SCHEMBL23714817

SCHEMBL23714817

CC(C)S(=O)(=O)c1cccc(C(=O)NCC(=O)Nc2nc(-c3cc(C#N)cc(-c4ccc(CN)cc4)c3)cs2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 4/20 0.40
▸ GPR139 Q6DWJ6 1/20 0.40
▸ CSNK2A2 P19784 1/20 0.40
▸ CSNK2B P67870 1/20 0.40
▸ CSNK2A1 P68400 1/20 0.40
▸ CSNK2A3 Q8NEV1 1/20 0.40
▸ ALDH1A1 P00352 4/20 0.39
▸ LMNA P02545 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ KDM4A O75164 2/20 0.39
▸ KDM4B O94953 2/20 0.39
▸ KDM5B Q9UGL1 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ MAPT P10636 5/20 0.39
▸ HPGD P15428 3/20 0.39
▸ KDM5C P41229 1/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ ROCK2 O75116 1/20 0.39
▸ KMT2A Q03164 3/20 0.38
▸ MEN1 O00255 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23705408 0.92 MAPT (0.45) GPR139ALDH1A1LMNASMN1; SMN2KDM4A
SCHEMBL23714825 0.90 MAPT (0.43) RORCGPR139CSNK2A2CSNK2BCSNK2A1
SCHEMBL23714962 0.89 HDAC1 (0.38) RORCGPR139CSNK2A2CSNK2BCSNK2A1
SCHEMBL23704933 0.89 MAPT (0.48) GPR139ALDH1A1LMNASMN1; SMN2KDM4A
SCHEMBL23714804 0.88 GPR139 (0.47) RORCGPR139CSNK2A2CSNK2BCSNK2A1
SCHEMBL23705295 0.88 GPR139 (0.49) RORCGPR139CSNK2A2CSNK2BCSNK2A1
SCHEMBL25179667 0.88 CSNK2A2 (0.41) RORCGPR139CSNK2A2CSNK2BCSNK2A1
SCHEMBL25187645 0.88 GPR139 (0.44) RORCGPR139CSNK2A2CSNK2BCSNK2A1
SCHEMBL23714795 0.86 MAPT (0.45) RORCALDH1A1LMNASMN1; SMN2KDM4A
SCHEMBL21241898 0.82 MAPT (0.55) RORCALDH1A1LMNASMN1; SMN2KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 — — CN disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RORC 2157/4885GPR139 4225/4885CSNK2A2 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback